- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00761826
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
July 17, 2018 updated by: Carl Zeiss Meditec, Inc.
A Prospective Multicenter Trial To Evaluate The Safety And Effectiveness Of The MEL 80 Excimer Laser Using LASIK (Laser In Situ Keratomileusis) For The Correction Of Naturally Occuring Mixed Astigmatism Up To 6.0 D
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of mixed astigmatism up to 6.0 D, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
LASIK has become one of the most common refractive eye procedures performed in the country.
In the mixed astigmatism procedure, a combination of both a steepening (hyperopic treatment) and a flattening (myopic treatment) occur on the corneal surface.
The surgeon will produce a standard keratomileusis flap using a microkeratome, exposing the corneal stroma.
Recontouring under the flap is then accomplished by the removal of tissue from the stroma with the laser.
This recontouring results in an altering of effective lens power of the central cornea, measured in diopters (D).
The MEL 80 Excimer Laser System will be evaluated for its ability to create accurate and stable mixed astigmatic refractive correction results.
Study Type
Interventional
Enrollment (Actual)
126
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92106
- US Navy Refractive Surgery Center
-
-
Colorado
-
Greenwood Village, Colorado, United States, 80111
- Dishler Laser Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64055
- Discover Vision Centers
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Fine, Hoffman, and Packer
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53717
- Davis Duehr Dean Eye Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Naturally occurring mixed astigmatism when the magnitude of cylinder (up to 6.0 D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs, at the spectacle plane;
- Have a stable refraction for at least the past twelve months, as demonstrated by a change of less than or equal to 0.50 D preoperative spherical equivalent shift over twelve months prior to surgery;
- Discontinue use of contact lenses at least 2 weeks for hard contacts and 3 days for soft lenses prior to the preoperative examination;
- Hard contact lens wearers must have two central keratometry readings and two manifest refractions taken at least one week apart that do not differ by more than 0.50 D
- Have visual acuity correctable to at least 20/40 in both eyes
- Have no more than 0.75 D of latent hyperopia as determined by the difference between the preoperative manifest refractive spherical equivalent (MRSE) and cycloplegic refractive spherical equivalent (CRSE);
- Be at least 18 years of age
- Corneal topography should be normal;
- The operative eye must be targeted for emmetropia;
- Be willing and able to return for scheduled follow-up examinations for twelve months after surgery;
- and provide written informed consent.
Exclusion Criteria:
- History of anterior segment pathology, including cataracts (in the operative eye);
- Clinically significant dry eye syndrome unresolved by treatment;
- Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars within the ablation zone or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease;
- Ophthalmoscopic signs of keratoconus (or keratoconus suspect);
- Required ablation is deeper than 250 microns from the corneal endothelium;
- Irregular or unstable (distorted/not clear) corneal mires on central keratometry readings;
- Blind in the fellow eye;
- Previous intraocular or corneal surgery of any kind in the operative eye(s), including any type of surgery for either refractive or therapeutic purposes;
- History of ocular Herpes zoster or Herpes simplex keratitis;
- History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP >21 mm Hg;
- Diabetes, diagnosed autoimmune disease, connective tissue disease or clinically significant atopic syndrome;
- Immunocompromised patients, or use of chronic systemic corticosteroid or other immunosuppressive therapy;
- Pregnant, lactating, or child-bearing potential and not practicing a medically approved method of birth control;
- Sensitivity to planned study medications;
- Simultaneous participation in other ophthalmic drug or device clinical trial.
- For Fellow (Second) Eyes in Simultaneous Bilateral Treatment Procedures
- 1. Flap complications during the first eye's surgery such as a free cap, partial flap, thin flap, or irregular flap.
- 2. Epithelial defect exceeding 2 mm x 2 mm in dimension, or clinically significant debris in the interface between the flap and underlying stroma for the first eye.
- 3. Severe blepharospasm in the first eye that may have prevented or impeded the completion of the keratectomy and/or the laser ablation procedure.
- 4. Poor subject cooperation with instructions for the first eye's surgery and/or poor subject fixation on the laser fixation target.
- 5. Aborted LASIK procedure in the first eye or PRK was performed in the first eye because LASIK was not possible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
At the point of stability, a minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.
Time Frame: Point of stability
|
Point of stability
|
A minimum of 85% of eyes should have an uncorrected visual acuity of 20/40 or better at the postoperative interval at which stability has been established.
Time Frame: Point of stability
|
Point of stability
|
A minimum of 95% of eyes should have a change of < 1.00 D in manifest refraction spherical equivalent (MRSE) between 2 refractions performed at least 3 months apart, and the mean rate of MRSE change per month should be < 0.04 D.
Time Frame: Point of stability
|
Point of stability
|
Distance BSCVA of worse than 20/40 at the postoperative interval at which stability has been established should occur in less than 1.0 % of eyes that had a BSCVA of 20/20 or better before surgery.
Time Frame: Point of stability
|
Point of stability
|
Loss of more than 2 lines of BSCVA should occur in less than 5.0 % of eyes.
Time Frame: Postoperative visits
|
Postoperative visits
|
Incidence of adverse events to occur in less than 1% of eyes
Time Frame: Postoperative visits
|
Postoperative visits
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subject Satisfaction: As measured by a subjective questionnaire, and will be considered as a secondary efficacy variable.
Time Frame: Postoperative visits 3, 6, 9 and 12 months
|
Postoperative visits 3, 6, 9 and 12 months
|
Incidence of complications
Time Frame: Postoperative visits
|
Postoperative visits
|
Patient Symptoms: As measured by a subjective questionnaire, will be considered as a secondary safety variable.
Time Frame: Preoperative and Postoperative visits 3, 6, 9 and 12 months
|
Preoperative and Postoperative visits 3, 6, 9 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Doane, MD, Discover Vision Centers
- Principal Investigator: Richard Hoffman, MD, FIne, Hoffman, and Packer LLC
- Principal Investigator: Howard Fine, MD, FIne, Hoffman, and Packer LLC
- Principal Investigator: Mark Packer, MD, FIne, Hoffman, and Packer LLC
- Principal Investigator: David Tanzer, MD, US Navy Refractive Surgery Center, San Diego, CA
- Principal Investigator: John Vukich, MD, Davis Duehr Dean Eye Clinic
- Principal Investigator: Jon Dishler, MD, Dishler Laser Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
September 26, 2008
First Submitted That Met QC Criteria
September 26, 2008
First Posted (Estimate)
September 30, 2008
Study Record Updates
Last Update Posted (Actual)
July 19, 2018
Last Update Submitted That Met QC Criteria
July 17, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEL 80-2006-2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mixed Astigmatism
-
Ohio State UniversityActive, not recruitingAstigmatism BilateralUnited States
-
Coopervision, Inc.Completed
-
Cairo UniversityUnknown
-
Assiut UniversityCompleted
-
Ashford and St. Peter's Hospitals NHS TrustBausch & Lomb IncorporatedUnknown
-
Johnson & Johnson Vision Care, Inc.Completed
-
Ziemer Ophthalmic Systems AGTigermed Consulting Co., LtdRecruitingMyopic AstigmatismChina
-
Bausch & Lomb IncorporatedCompleted
-
Staar Surgical CompanyActive, not recruiting
-
Coopervision, Inc.CompletedAstigmatism BilateralCanada
Clinical Trials on MEL 80 Mixed Astigmatism Treatment
-
Carl Zeiss Meditec, Inc.Completed
-
Carl Zeiss Meditec, Inc.Completed
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); American Psychological...TerminatedAlcohol Use Disorder (AUD) | Subjective Response to Alcohol (SR)United States
-
Yungjin Pharm. Co., Ltd.CompletedChronic Obstructive Pulmonary DiseaseUnited States
-
Universidad de GranadaCompletedMental Health Disorder | Healthy LifestyleSpain
-
Washington University School of MedicineCompleted
-
UroGen Pharma Ltd.CompletedCarcinoma of Urinary Bladder, SuperficialIsrael, Spain, Italy, Switzerland
-
CTI BioPharmaCovanceCompleted